Your browser doesn't support javascript.
loading
Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy.
Cho, Hourin; Abe, Seiichiro; Nonaka, Satoru; Suzuki, Haruhisa; Yoshinaga, Shigetaka; Okuma, Kae; Yamamoto, Shun; Daiko, Hiroyuki; Kato, Ken; Sekine, Shigeki; Boku, Narikazu; Saito, Yutaka.
Afiliação
  • Cho H; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Abe S; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Nonaka S; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Suzuki H; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Yoshinaga S; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
  • Okuma K; Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yamamoto S; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Daiko H; Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Kato K; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Sekine S; Division of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Boku N; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Saito Y; Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Dis Esophagus ; 37(5)2024 Apr 27.
Article em En | MEDLINE | ID: mdl-38266034
ABSTRACT
Endoscopic resection (ER) of esophageal squamous cell carcinoma (ESCC) is evaluated pathologically, and additional treatment is recommended for cases resulting in non-curative resection, defined as pMM with lymphovascular invasion (LVI), pSM, or positive vertical margin. This study aimed to assess long-term outcomes and risk factors for recurrence in patients with ESCC treated with non-curative ER followed by additional chemoradiotherapy (CRT). We retrospectively reviewed the clinical courses of patients who underwent non-curative ER followed by additional CRT for ESCCs between August 2007 and December 2017. Recurrence rates and risk factors for recurrence were analyzed. Among 97 patients with non-curative ER, 73 underwent additional CRT. With a median follow-up period of 71 months, recurrences were observed in 10 (14%) of 73 patients, with a median interval of 24.5 (1-59 months). The 3- and 5-year recurrence-free survival were 89 and 85%, respectively, and the 3- and 5-year overall survival rates were 96 and 91%, respectively. Multivariate analysis showed that lymphatic invasion was an independent risk factor for recurrence in patients with non-curative ESCC receiving additional CRT. Among the 10 patients with recurrence, 4, 3, 2, and 1 underwent surgery, chemotherapy, supportive care, and CRT, respectively. Notably, all four patients who underwent surgery survived, regardless of regional and/or distant lymph node metastasis. Lymphatic invasion is an independent risk factor for the recurrence of non-curative ESCCs. Careful follow-up is required for at least 5 years after ER with additional CRT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Esofagoscopia / Esofagectomia / Quimiorradioterapia / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Esofagoscopia / Esofagectomia / Quimiorradioterapia / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article